ABOUT US
Our mission is to translate MYC synthetic lethality into biomarker-embedded cancer therapies that deliver meaningful improvements in clinical outcomes
Pioneering First-in-Class MYC-Synthetic Lethality Therapy
Founded in 2016 and headquartered in Chengdu Tianfu International BioTown, China, ACB focuses on MYC-driven malignancies that remain poorly served by current therapies. Our programs integrate MYC biology, cell-cycle regulation, cellular architecture, and tumor immunology to advance cancer treatment through MYC synthetic lethality—targeting the malignant state created by oncogenic drivers rather than inhibiting individual drivers in isolation.
OUR MISSION
We develop clinical-stage cancer therapeutics based on MYC synthetic lethality (MYC-SL). In close scientific partnership with the J. Michael Bishop Institute of Cancer Research (JMBI), we transform foundational discoveries in MYC biology into targeted therapies for aggressive solid tumors.










